Welcome to our dedicated page for Inovio Pharmaceuticals news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceuticals stock.
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is a pioneering United States-based biotechnology company dedicated to combating cancers and infectious diseases through DNA medicines. The company's innovative approach harnesses active DNA-based immunotherapies and vaccines to both treat and prevent these conditions.
Inovio's core technology revolves around its DNA plasmids, which are small circular DNA molecules crafted to produce specific proteins to target and fight diseases, delivered via their proprietary CELLECTRA® electroporation devices. This technology enables the body to produce its own disease-fighting proteins and immune responses, without the need for traditional adjuvants or nanoparticles.
The company's flagship candidate, INO-3107, targets Recurrent Respiratory Papillomatosis (RRP), a chronic and rare disease caused by HPV-6 and HPV-11. Inovio has shown significant clinical progress with INO-3107, and after receiving Breakthrough Therapy designation and Orphan Drug designation from both the FDA and the European Commission, it is on track to submit a Biologics License Application (BLA) under the FDA's accelerated approval program. With successful clinical trials demonstrating a robust immune response and a reduction in the need for surgical interventions, INO-3107 stands as a potential game-changer for RRP patients.
In addition to INO-3107, Inovio's expansive product pipeline includes several other promising candidates in various stages of development. These include INO-3112 for HPV-16/18 positive head and neck cancer, INO-4201 as an Ebola vaccine booster, and INO-5401 for glioblastoma, showcasing the versatility and broad applicability of the company's DNA medicine platform.
Inovio has established numerous strategic partnerships and collaborations to enhance its research and development efforts. Key partners include Roche, MedImmune, the University of Pennsylvania, DARPA, Drexel University, NIH, and the U.S. Military HIV Research Program. These collaborations not only bolster Inovio's scientific capabilities but also facilitate the swift advancement of its clinical programs.
Financially, Inovio has maintained a disciplined approach to managing its resources. The company recently projected its cash runway to extend into the second quarter of 2025, following positive feedback from the FDA on the accelerated approval pathway for INO-3107. This financial stability is crucial as Inovio prepares for potential commercialization of its lead candidates.
Inovio's commitment to innovation and its effective strategic execution position it as a formidable player in the biopharmaceutical industry, dedicated to bringing groundbreaking DNA medicine solutions to market. For more information, visit www.inovio.com.
INOVIO (NASDAQ: INO) announced positive results from a Phase 1b clinical trial of INO-4201, a DNA vaccine candidate as a booster for individuals previously vaccinated with Ervebo. Conducted with 46 participants, the trial demonstrated that INO-4201 was well-tolerated and boosted humoral responses in 100% of treated subjects (36 of 36). Neutralizing titers were significantly higher in the INO-4201 group compared to placebo, with responses maintained even 24 weeks later. The trial was sponsored by Geneva University Hospitals and funded by DARPA. The results emphasize the potential of INO-4201 for future Ebola Virus Disease prevention.
INOVIO (NASDAQ: INO) announced a strategic reorganization aimed at enhancing operational efficiency and advancing its DNA medicine programs. Key elements include an 11% reduction in headcount, expected to yield annual savings of approximately $4.3 million, and a one-time restructuring charge of around $1.1 million anticipated in Q1 2023. The reorganization follows the discontinuation of certain clinical development programs in late 2022. INOVIO confirmed that data readouts for its product candidates, INO-3107 and VGX-3100, are projected for the first quarter of 2023, aligning with its focus on HPV-associated diseases.
INOVIO (NASDAQ: INO) has announced the discontinuation of its product candidates for Lassa Fever (INO-4500) and Middle East Respiratory Syndrome (MERS) (INO-4700) after initial study analyses by CEPI. Despite well-tolerated trials in Ghana and Jordan, the two-dose regimen did not meet the selection criteria for further development. INOVIO emphasizes its commitment to its DNA medicine candidates and future collaborations with CEPI. The company plans to publish data to support ongoing research.
INOVIO (NASDAQ: INO) announced positive interim Phase 1/2 data for INO-3107, a potential treatment for recurrent respiratory papillomatosis, indicating a median decrease of three surgical interventions in 76% of participants. The company reported Q3 2022 revenue of $9.2 million, significantly up from $292,000 in 2021, primarily due to a contract with the U.S. Department of Defense. INOVIO also updated its cash runway guidance, now extending into Q1 2025. However, net loss for the quarter was $37.8 million, an improvement from the previous year's $60.2 million.
INOVIO (NASDAQ:INO) has announced the discontinuation of internal funding for INO-4800, its COVID-19 heterologous booster vaccine, due to reduced global demand and changes in regulatory conditions. CEO Dr. Jacqueline Shea emphasized the need to reallocate resources towards other promising candidates such as INO-3107 and INO-5401, which have shown positive Phase 1/2 results. Meanwhile, Advaccine in China will continue developing INO-4800 independently. INOVIO remains focused on advancing its DNA medicines technology for various diseases.
INOVIO (NASDAQ: INO) announced it will release its third quarter 2022 financial results on November 8, 2022, post-market close. Following the announcement, the company will host a live conference call and webcast at 4:30 p.m. ET to discuss the results and provide a general business update. Interested parties can access the live and archived audio presentation via their investor relations page. INOVIO focuses on developing DNA medicines for infectious diseases, cancer, and HPV-related conditions.
INOVIO (NASDAQ: INO) announced positive interim results from a Phase 1/2 trial of INO-3107 for treating HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP). Out of 21 participants, 76% saw a reduction in surgical interventions compared to the previous year, with 6 participants surgery-free. INO-3107 also demonstrated statistical significance in its primary endpoint and was well-tolerated. The treatment induced both CD4 and CD8 T cell responses against HPV types, suggesting potential as a first-in-class therapeutic option for RRP.
INOVIO (NASDAQ: INO) announced equity grants to two newly hired employees, including a Vice President of Clinical Development, on August 31, 2022. The grants comprise 5,000 restricted stock units (RSUs) and options for 26,250 shares of common stock, approved by the Compensation Committee under the 2022 Inducement Plan. The RSUs will vest over three years, and the stock options have an exercise price of $2.29, aligned with the stock's closing price on the Grant Date.
INOVIO (NASDAQ:INO), a biotechnology company focused on DNA medicines, announced that President and CEO Jacqueline Shea, Ph.D., will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, starting at 7:00 AM ET. The conference will feature one-on-one meetings with registered investors and a webcast available on the INOVIO Investor Relations Events page, with replays accessible for 90 days post-event. INOVIO specializes in developing treatments for infectious diseases and cancer.
INOVIO (NASDAQ: INO) announced financial results for Q2 2022, reporting revenue of $784,000, up from $273,000 in Q2 2021. The company extended its cash runway into Q3 2024 through a corporate restructuring, involving an 18% workforce reduction and expected 30% reduction in operating expenses. Positive data from a Phase 1/2 trial of INO-5401 for glioblastoma was presented at ASCO. Despite these advancements, net loss widened to $108.5 million, or $0.46 per share, from $82.1 million, or $0.39 per share, in the prior year.
FAQ
What is the current stock price of Inovio Pharmaceuticals (INO)?
What is the market cap of Inovio Pharmaceuticals (INO)?
What is Inovio Pharmaceuticals' primary focus?
What is INO-3107?
What is the CELLECTRA® device?
Who are some of Inovio’s key partners?
What financial outlook has Inovio projected?
What is INO-3112?
How does Inovio's DNA medicines platform work?
What are some of Inovio’s recent achievements?
Where can I find more financial information about Inovio?
What is Inovio's approach to commercialization?
